The ubiquitin proteasome system contains a plethora of novel therapeutic targets. Progenra's ability to discover novel structures employing its high throughput assays has created several opportunities for establishing partnerships with other companies.
Recognizing that: 1) there is still much to discover in the ubiquitin-proteasome system; and 2) there is a need for rigorous validation of ubiquitin proteasome system targets, Progenra encourages academic laboratories to contact us with potential collaborative projects. Progenra is especially interested in prospective collaborations with translational potential.
We are pleased to have collaborations with several leading national and international academic institutions.
|Baylor College of Medicine||Tokyo University|
|Brigham & Women's Hospital||Trinity College Dublin|
|Children's Hospital of Philadelphia||University of Alabama at Birmingham|
|Chinese Academy of Sciences||University of Alberta|
|Harvard University Dana-Farber Cancer Institute||University of California, San Diego|
|Emory University||University of California, Los Angeles|
|Curie Institute Paris||University of Glasgow|
|Johns Hopkins University School of Medicine||University of Illinois Chicago`|
|Karolinska Institute||University of Iowa|
|Kumamoto University||University of Michigan Medical Center|
|Louisiana State University||University of Oxford|
|Mayo Clinic||University of Pennsylvania School of Medicine|
|Massachusetts General Hospital||University of Pittsburgh|
|Northwestern University||University of Queensland|
|Purdue University||University of Toronto|
|Scripps Institute||Virginia Tech|